Professor Chong Zhao is currently a Chief Physician, Professor and Master supervisor in the Department of Nasopharyngeal Carcinoma/Radiation Oncology of Sun Yat-sen University Cancer Center. He has been engaged in the area of radiation oncology for more than 30 years, and specializes in the diagnosis, radiotherapy and combined treatment of head and neck cancers, especially the intensity modulated radiotherapy (IMRT), chemoradiotherapy, targeted therapy, immunotherapy and nutritional therapy on nasopharyngeal carcinoma. Prof. Zhao is one of the top radiation oncologists in China, who lead in investigating the IMRT technique and optimizing target volumes delineation and dose modification for NPC from 2001. He has been in charge of or participated in more than 30 research projects supported by international, national or provincial funds. He is now leading several multicenter clinical trials in China. He has published more than 100 peer-reviewed papers in renowned international journals such as Annals of Oncology and International Journal of Radiation Oncology Biology Physics. Prof. Zhao is also the recipient of three National Science and Technology Progress Awards (2nd level) and one provincial and ministerial awards (1st level), including the Chinese Medical Science and Technology Award, among many more. Besides, he is the leader member of many academic committees.

Diagnosis, radiotherapy and combined treatment of head and neck cancers and has particular expertise in intensity modulated radiotherapy and chemo-radiotherapy concerning nasopharyngeal carcinoma.

Degrees, Board Certification
2019.06    Ph.D., Wuhan University
1986.06    M.B.B.S., Sun Yat-sen Medical University

Undergraduate Education
1980.09-1986.06   Sun Yat-sen Medical University

Post-graduate, Research, and Specialty Training
2016.09-2019.06    Wuhan University
2009.04-2009.10   Principles and practice of clinical research, The National Institutes of Health Clinical Center
2005.09-2007.09   Receive the Master's degree program, Sun Yat-sen University
1997.12-1998.01   Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

Seletected publications

1. Zhao C, Miao JJ, Shen GZ, Li JG, Shi M, Zhang N, Hu GQ, Chen XZ, Hu XF, Wu SX, Chen JX, Shao XF, Wang L, Han F, Mai HQ, Chua MLK, Xie C. Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody combined with Cisplatin and 5-Fluorouracil in Patients with Metastatic Nasopharyngeal Carcinoma after Radical Radiotherapy: A Multicentre, Open-label, Phase II Clinical Trial. Ann Oncol. 2019 Jan 23.

2. Wu X, Huang PY, Peng PJ, Lu LX, Han F, Wu SX, Hou X, Zhao HY, Huang Y, Fang WF, Zhao YY, Xue C, Hu ZH, Zhang J, Zhang JW, Ma YX, Liang WH, Zhao C (Co-last Corresponding), Zhang L. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Annals of Oncology,2013; 24: 2131–2136.

3. Miao JJ, Di MP, Chen BY, Wang L, Cao YQ, Xiao WW, Wong KH, Huang L, Zhu MY, Huang HG, Huang SM, Han F, Deng XW, Xiang YQ, Lv X, Xia WX, Tan SH, Wee JTS, Guo X, Chua MLK, Zhao C. A Prospective 10-year Observational Study of Reduction of Radiotherapy Clinical Target Volume and Dose in Early-stage Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2020 Apr 6. pii: S0360-3016(20)30959-7.

4. Zhao C, Miao JJ, Hua YJ, Wang L, Han F, Lu LX, Xiao WW, Wu HJ, Zhu MY, Huang SM, Lin CG, Deng XW, Xie CH. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):836-844.

5. Chen JZ, Le QT, Han F, Lu LX, Huang SM, Lin CG, Deng XW, Cui NJ, Zhao C. Results of a Phase II Study Examining the Effects of Omitting Elective Neck Irradiation to Nodal Levels IV and Vb in Patients with N0-1 Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics,2013; 85(4):929-934.

6. Di MP, Wang M, Miao JJ, Chen BY, Huang HG, Lin CY, Jian YT, Li Y, Ouyang Y, Chen XF, Wang L, Zhao C. CHAF1B induces radioresistance by promoting DNA damage repair in nasopharyngeal carcinoma. Biomed Pharmacother. 2020 Mar; 123:109748.

7. Miao JJ, Wang L, Zhu MY, Xiao WW, Wu HJ, Di MP, Huang YQ, Huang SM, Han F, Deng XW, Guo X, Zhao C. Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy. Oral Oncol. 2019 Mar; 90:126-133.

8. Peng YL, Chen L, Shen GZ, Li YN, Yao JJ, Xiao WW, Yang L, Zhou S, Li JX, Cheng WQ, Guan Y, Xia HQ, Liu S, Zhao C (Co-last Corresponding), Deng XW. Interobserver variations in the delineation of target volumes and organs at risk and their impact on dose distribution in intensity-modulated radiation therapy for nasopharyngeal carcinoma. Oral Oncol. 2018 Jul; 82:1-7.

9. Li Y, Tang LQ, Liu LT, Guo SS, Liang YJ, Sun XS, Tang QN, Bei JX, Tan J, Chen S, Ma J, Zhao C (3rd corresponding), Chen QY, Mai HQ. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. Cancer Res Treat. 2018 Oct;50(4):1304-1315.

10. Shen GZ, Xiao WW, Han F, Fan W, Lin XP, Lu L, Zheng L, Yue N, Haffty B, Zhao C (Co-last Corresponding), Deng X. Advantage of PET/CT in Target Delineation of MRI-negative Cervical Lymph Nodes in Intensity-Modulated Radiation Therapy Planning for Nasopharyngeal Carcinoma. J Cancer. 2017 Nov 6;8(19):4117-4123.

Updated May 2020 by International Office, Sun Yat-sen University Cancer Center